Upcoming Earnings: Q2 '26
Estimated EPS
-$0.78
Estimated Rev
$0M
$BLTE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.68 down -51.11% YoY • Belite Bio anticipates completing its rolling NDA submission for tinlarebant in STGD1 to the FDA in the second quarter of 2026, an important regulatory milestone for the company.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.78 | -- | -- | N/A |
Q1 '26 | -$0.63 | -$0.34 | 46.45% | BEAT |
Q4 '25 | -$0.55 | -$0.38 | 30.43% | BEAT |
Q3 '25 | -$0.49 | -$0.65 | -33.33% | MISSED |
Q2 '25 | -$0.41 | -$0.50 | -21.95% | MISSED |